Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INZYNASDAQ:IPHANASDAQ:MASSNASDAQ:PROF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINZYInozyme Pharma$3.99$2.67$0.72▼$6.24$257.60M2.27891,700 shs1.02 million shsIPHAInnate Pharma$1.80$2.09$1.29▼$3.51$165.92M0.26186,555 shs20,145 shsMASS908 Devices$6.64-9.5%$5.77$1.81▼$8.06$263.22M0.291.04 million shs668,486 shsPROFProfound Medical$6.01-5.4%$5.29$3.90▼$11.42$190.84M0.4864,794 shs22,036 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINZYInozyme Pharma0.00%+0.50%+0.76%+310.87%-10.34%IPHAInnate Pharma0.00%-3.23%-16.47%-8.40%-15.89%MASS908 Devices-9.54%-7.65%+38.33%+65.59%+24.34%PROFProfound Medical-5.35%-11.36%+17.15%-10.03%-32.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINZYInozyme Pharma2.6591 of 5 stars4.23.00.00.00.62.50.0IPHAInnate Pharma2.9505 of 5 stars3.85.00.00.01.91.70.0MASS908 Devices2.1718 of 5 stars1.34.00.00.03.15.00.6PROFProfound Medical2.1576 of 5 stars3.52.00.00.00.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINZYInozyme Pharma 2.44Hold$11.75194.49% UpsideIPHAInnate Pharma 3.50Strong Buy$11.00511.11% UpsideMASS908 Devices 2.50Moderate Buy$5.33-19.68% DownsidePROFProfound Medical 3.00Buy$11.5091.35% UpsideCurrent Analyst Ratings BreakdownLatest MASS, PROF, INZY, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/24/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/10/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/9/2025PROFProfound MedicalRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy4/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/AIPHAInnate Pharma$12.62M13.15N/AN/A$0.11 per share16.36MASS908 Devices$59.63M3.99N/AN/A$3.29 per share2.02PROFProfound Medical$11.86M15.23N/AN/A$2.01 per share2.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/AMASS908 Devices-$72.21M-$0.54N/AN/AN/A-28.80%-27.10%-20.49%8/5/2025 (Estimated)PROFProfound Medical-$27.82M-$1.22N/AN/AN/A-269.35%-70.41%-57.22%8/6/2025 (Estimated)Latest MASS, PROF, INZY, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/13/2025Q1 2025MASS908 Devices-$0.27-$0.22+$0.05$1.23$11.90 million$11.78 million5/8/2025Q1 2025PROFProfound Medical-$0.29-$0.36-$0.07-$0.36$4.78 million$2.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINZYInozyme PharmaN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AMASS908 DevicesN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINZYInozyme Pharma0.652.192.19IPHAInnate Pharma2.522.602.60MASS908 DevicesN/A7.626.97PROFProfound Medical0.0911.3110.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINZYInozyme Pharma88.30%IPHAInnate Pharma0.16%MASS908 Devices88.06%PROFProfound Medical47.86%Insider OwnershipCompanyInsider OwnershipINZYInozyme Pharma12.18%IPHAInnate Pharma31.89%MASS908 Devices23.70%PROFProfound Medical1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableIPHAInnate Pharma22092.18 million62.78 millionNot OptionableMASS908 Devices6035.86 million27.36 millionOptionablePROFProfound Medical15030.05 million29.60 millionOptionableMASS, PROF, INZY, and IPHA HeadlinesRecent News About These Companies‘Profound loss’: Police recruit dies after suffering medical emergency during final fitness testJune 23 at 8:55 PM | ky3.comWexford family with ‘profound medical needs’ removed from choice-based letting system as council accused of lacking ‘humanity’June 16, 2025 | msn.comMedical experts unveil major clues to the type of "incurable" cancer King Charles could have been diagnosed withJune 14, 2025 | skynews.com.auProfound Medical (NASDAQ:PROF) Shares Up 17.4% - What's Next?June 11, 2025 | marketbeat.comPowers Health Partners With Profound Research to Expand Clinical Trial Access in Northwest IndianaJune 10, 2025 | miamiherald.comFamed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®June 4, 2025 | financialpost.com1 Magnificent Healthcare Stock Down 80% to Buy and Hold ForeverMay 22, 2025 | fool.caProfound Medical Corp. (NASDAQ:PROF) CEO Purchases $43,312.99 in StockMay 21, 2025 | insidertrades.comWhy Profound Medical Corp.’s (PROF) Stock Is Up 5.07%May 16, 2025 | aaii.comProfound Medical Annual General and Special Meeting of Shareholders Voting ResultsMay 14, 2025 | globenewswire.comProfound Medical targets 70%-75% growth in 2025 with new TULSA AI module launchMay 9, 2025 | msn.comProfound Medical Corporation (PROF) Q1 2025 Earnings Conference Call TranscriptMay 9, 2025 | seekingalpha.comProfound Medical Announces First Quarter 2025 Financial ResultsMay 9, 2025 | manilatimes.netProfound Medical (PROF) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comProfound Medical Reports Strong Q1 2025 Growth and Highlights TULSA-PRO AdvancementsMay 8, 2025 | tipranks.com1 Magnificent Canadian Stock Down 52% to Buy and Hold ForeverMay 7, 2025 | msn.comStrength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?May 5, 2025 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROFMay 1, 2025 | accessnewswire.comProfound Medical: In Serious Trouble Despite Projected GrowthApril 30, 2025 | seekingalpha.comProfound Medical to Present at 2025 Healthcare Investor ConferenceApril 30, 2025 | tipranks.comProfound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 30, 2025 | financialpost.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeWhy Quantum Computing Inc. Is the Quiet Winner in Quantum StocksBy Jeffrey Neal Johnson | June 18, 2025View Why Quantum Computing Inc. Is the Quiet Winner in Quantum StocksNuclear Stocks Reach Critical Mass: The Time to Buy Is NowBy Thomas Hughes | May 27, 2025View Nuclear Stocks Reach Critical Mass: The Time to Buy Is NowAXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionBy Leo Miller | May 31, 2025View AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsMASS, PROF, INZY, and IPHA Company DescriptionsInozyme Pharma NASDAQ:INZY$3.99 0.00 (0.00%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.00 +0.00 (+0.13%) As of 06/23/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Innate Pharma NASDAQ:IPHA$1.80 0.00 (0.00%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$1.83 +0.03 (+1.67%) As of 06/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.908 Devices NASDAQ:MASS$6.64 -0.70 (-9.54%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$6.76 +0.13 (+1.88%) As of 06/23/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Profound Medical NASDAQ:PROF$6.01 -0.34 (-5.35%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$6.00 0.00 (-0.08%) As of 06/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
